SLC 0111

Drug Profile

SLC 0111

Alternative Names: SLC-0111

Latest Information Update: 21 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SignalChem Lifesciences
  • Developer SignalChem Lifesciences; Welichem Biotech
  • Class Cytostatics; Small molecules
  • Mechanism of Action Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 18 Jul 2016 SignalChem Lifesciences and Welichem Biotech agree to co-develop SLC 0111 (SignalChem Lifesciences pipeline, July 2016)
  • 14 Apr 2016 Pharmacodynamics data from a preclinical trial in Pancreatic ductal adenocarcinoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 14 Apr 2016 SignalChem Lifesciences plans a phase Ib trial in Pancreatic ductal adenocarcinoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top